Table 2. Results from the validation study of miR-17, miR-21, and miR-145-expression in the normal-adenoma-adenocarcinoma sequence.
Normal | Adenoma | Adenocarcinoma | |
---|---|---|---|
miR-17 | |||
N | 24 | 24 | 24 |
Low | 24 (100%) | 1 (4%) | 1 (4%) |
High | 0 | 23 (96%) | 23 (96%) |
miR-21 | |||
N | 24 | 24 | 22 a |
Low | 24 (100%) | 7 (29%) | 0 |
Moderate | 0 | 16 (67%) | 7 (32%) |
High | 0 | 1 (4%) | 15 (68%) |
miR-145 | |||
N | 23 a | 22 a | 22 a |
Low | 0 | 11 (50%) | 19 (86%) |
High | 23 (100%) | 11 (50%) | 3 (14%) |
aData missing due to specimens failing to include all three compartments.